APA (7th ed.) Citation

Taylor, P. C., Askari, A., Choy, E., Ehrenstein, M. R., Else, S., & Nisar, M. K. (2023). Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. BMC Medicine, 21(1), 1. https://doi.org/10.1186/s12916-023-02746-5

Chicago Style (17th ed.) Citation

Taylor, Peter C., Ayman Askari, Ernest Choy, Michael R. Ehrenstein, Sara Else, and Muhammad K. Nisar. "Approaches to Optimising Access to NICE-approved Biologic Anti-TNFs for Patients with Rheumatoid Arthritis with Moderately Active Disease." BMC Medicine 21, no. 1 (2023): 1. https://doi.org/10.1186/s12916-023-02746-5.

MLA (9th ed.) Citation

Taylor, Peter C., et al. "Approaches to Optimising Access to NICE-approved Biologic Anti-TNFs for Patients with Rheumatoid Arthritis with Moderately Active Disease." BMC Medicine, vol. 21, no. 1, 2023, p. 1, https://doi.org/10.1186/s12916-023-02746-5.